Drug Trial Radar · NCT06399185
Effect of Dexmedetomidine and Esketamine on Catheter-related Bladder Discomfort
Last checked: Nov 20, 2026Latest source record: Jul 31, 2025 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Recruiting
Enrollment
1,740
Planned (sponsor's estimate)
Start
Jun 6, 2024
Primary completion
Apr 2027
Study completion May 2027
Sponsor
- Lead sponsor
- Peking University First HospitalAcademic, hospital or other
- Sponsor type
- Academic, hospital or other
- Collaborators
- Peking University Shenzhen Hospital
- First posted
- May 3, 2024
Design
- Study type
- Interventional
- Phase
- Phase 4
- Allocation
- Randomized
- Model
- Factorial
- Masking
- Triple (participant, care provider, outcomes assessor)
- Primary purpose
- Treatment
- FDA-regulated drug
- No
- Who can join
- All sexes, from 18 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
Catheter-related bladder discomfort (CRBD) is common in patients awaking from general anesthesia with an urinary catheter. We suppose that that use of dexmedetomidine and/or esketamine during anesthesia may reduce the occurrence of CRBD. This 2x2 factorial randomized trial is designed to explore the effects of esketamine, dexmedetomidine, and their combination on the occurrence CRBD in patients undergoing transurethral urological surgery.
Conditions
- Urinary Catheter
- Catheter-related Bladder Discomfort
- Dexmedetomidine
- Esketamine
Interventions
Normal salineDrug
20 ml of normal saline is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
DexmedetomidineDrug
Dexmedetomidine 0.5 μg/kg, diluted with normal salinet o 20 ml, is infused intravenously at 60 ml/h after anesthesia induction but before surgery.
EsketamineDrug
Esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Combined dexmedetomidine-esketamineDrug
Dexmedetomidine 0.5 μg/kg and esketamine 0.25 mg/kg, diluted with normal saline to 20 ml, is infused intravenously at 80 ml/h after anesthesia induction but before surgery.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Incidence of catheter-related bladder discomfort (CRBD) within 24 hours after surgery.Time frame: Up to 24 hours after surgery.
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Peking University First Hospital
Beijing, Beijing Municipality, China · Recruiting
Peking University Shenzhen Hospital
Shenzhen, Guangdong, China · Recruiting
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.